You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCinacalcet
Accession NumberDB01012  (APRD00872)
TypeSmall Molecule
GroupsApproved
DescriptionCinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure.
Structure
Thumb
Synonyms
(R)-alpha-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
CNC
Mimpara
N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mylan-cinacalcettablet30 mgoralMylan Pharmaceuticals Ulc2016-06-29Not applicableCanada
Mylan-cinacalcettablet60 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-cinacalcettablet90 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Sandoz Cinacalcettablet90 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Cinacalcettablet30 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Cinacalcettablet60 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sensipartablet, coated60 mg/1oralAmgen Inc2004-04-04Not applicableUs
Sensipartablet, coated30 mg/1oralREMEDYREPACK INC.2013-04-01Not applicableUs
Sensipartablet, coated30 mg/1oralAvera Mc Kennan Hospital2015-03-17Not applicableUs
Sensipartablet60 mgoralAmgen Canada Inc2004-09-16Not applicableCanada
Sensipartablet, coated30 mg/1oralCardinal Health2004-04-04Not applicableUs
Sensipartablet, coated90 mg/1oralAmgen Inc2004-04-04Not applicableUs
Sensipartablet, coated30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sensipartablet90 mgoralAmgen Canada Inc2004-09-16Not applicableCanada
Sensipartablet, coated60 mg/1oralCardinal Health2004-04-04Not applicableUs
Sensipartablet, coated30 mg/1oralCarilion Materials Management2004-04-04Not applicableUs
Sensipartablet, coated60 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sensipartablet, coated30 mg/1oralAmgen Inc2004-04-04Not applicableUs
Sensipartablet30 mgoralAmgen Canada Inc2004-09-16Not applicableCanada
Sensipartablet, coated30 mg/1oralPhysicians Total Care, Inc.2010-03-02Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cinacalcettablet30 mgoralApotex Inc2016-05-20Not applicableCanada
Apo-cinacalcettablet60 mgoralApotex Inc2016-05-20Not applicableCanada
Apo-cinacalcettablet90 mgoralApotex Inc2016-05-20Not applicableCanada
Cinacalcet MylanFilm-coated tablet60 mgOral useMylan S.A.S.2015-11-19Not applicableEu
Cinacalcet MylanFilm-coated tablet90 mgOral useMylan S.A.S.2015-11-19Not applicableEu
Cinacalcet MylanFilm-coated tablet30 mgOral useMylan S.A.S.2015-11-19Not applicableEu
Cinacalcet MylanFilm-coated tablet60 mgOral useMylan S.A.S.2015-11-19Not applicableEu
Cinacalcet MylanFilm-coated tablet90 mgOral useMylan S.A.S.2015-11-19Not applicableEu
Cinacalcet MylanFilm-coated tablet30 mgOral useMylan S.A.S.2015-11-19Not applicableEu
Cinacalcet MylanFilm-coated tablet60 mgOral useMylan S.A.S.2015-11-19Not applicableEu
Cinacalcet MylanFilm-coated tablet30 mgOral useMylan S.A.S.2015-11-19Not applicableEu
Cinacalcet MylanFilm-coated tablet90 mgOral useMylan S.A.S.2015-11-19Not applicableEu
Cinacalcet MylanFilm-coated tablet30 mgOral useMylan S.A.S.2015-11-19Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cinacalcet hydrochloride
ThumbNot applicableDBSALT001463
Categories
UNIIUAZ6V7728S
CAS number226256-56-0
WeightAverage: 357.412
Monoisotopic: 357.170434324
Chemical FormulaC22H22F3N
InChI KeyInChIKey=VDHAWDNDOKGFTD-MRXNPFEDSA-N
InChI
InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
IUPAC Name
[(1R)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl})amine
SMILES
C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Phenylpropylamine
  • Naphthalene
  • Aralkylamine
  • Monocyclic benzene moiety
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
PharmacodynamicsCinacalcet is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues). Secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) is a progressive disease, associated with increases in parathyroid hormone (PTH) levels and derangements in calcium and phosphorus metabolism. Increased PTH stimulates osteoclastic activity resulting in cortical bone resorption and marrow fibrosis. The goals of treatment of secondary hyperparathyroidism are to lower levels of PTH, calcium, and phosphorus in the blood, in order to prevent progressive bone disease and the systemic consequences of disordered mineral metabolism. In CKD patients on dialysis with uncontrolled secondary HPT, reductions in PTH are associated with a favorable impact on bone-specific alkaline phosphatase (BALP), bone turnover and bone fibrosis. Cinacalcet reduces calcium levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium.
Mechanism of actionThe calcium-sensing receptors on the surface of the chief cell of the parathyroid gland is the principal regulator of parathyroid hormone secretion (PTH). Cinacalcet directly lowers parathyroid hormone levels by increasing the sensitivity of the calcium sensing receptors to activation by extracellular calcium, resulting in the inhibition of PTH secretion. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distribution
  • 1000 L
Protein bindingApproximately 93 to 97% bound to plasma proteins.
Metabolism

Metabolism is hepatic by multiple enzymes, primarily CYP3A4, CYP2D6, and CYP1A2. After administration of a 75 mg radiolabeled dose to healthy volunteers, cinacalcet was rapidly and extensively metabolized via: 1) oxidative N-dealkylation to hydrocinnamic acid and hydroxy-hydrocinnamic acid, which are further metabolized via ß-oxidation and glycine conjugation; the oxidative N-dealkylation process also generates metabolites that contain the naphthalene ring; and 2) oxidation of the naphthalene ring on the parent drug to form dihydrodiols, which are further conjugated with glucuronic acid.

SubstrateEnzymesProduct
Cinacalcet
Not Available
Hydrocinnamic acidDetails
Cinacalcet
Not Available
hydroxy-hydrocinnamic acidDetails
Route of eliminationCinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2. Renal excretion of metabolites was the primary route of elimination of radioactivity.
Half lifeTerminal half-life is 30 to 40 hours. The mean half-life of cinacalcet is prolonged by 33% and 70% in patients with moderate and severe hepatic impairment, respectively.
ClearanceNot Available
ToxicityDoses titrated up to 300 mg once daily have been safely administered to patients on dialysis. Overdosage of cinacalcet may lead to hypocalcemia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9927
Caco-2 permeable+0.7058
P-glycoprotein substrateSubstrate0.5309
P-glycoprotein inhibitor IInhibitor0.8512
P-glycoprotein inhibitor IIInhibitor0.6937
Renal organic cation transporterInhibitor0.5305
CYP450 2C9 substrateNon-substrate0.7761
CYP450 2D6 substrateSubstrate0.8293
CYP450 3A4 substrateNon-substrate0.5425
CYP450 1A2 substrateInhibitor0.9206
CYP450 2C9 inhibitorNon-inhibitor0.8572
CYP450 2D6 inhibitorInhibitor0.8188
CYP450 2C19 inhibitorInhibitor0.8795
CYP450 3A4 inhibitorInhibitor0.7166
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5904
Ames testNon AMES toxic0.5152
CarcinogenicityNon-carcinogens0.8785
BiodegradationNot ready biodegradable0.9932
Rat acute toxicity2.8511 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9175
hERG inhibition (predictor II)Inhibitor0.8494
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Amgen inc
Packagers
Dosage forms
FormRouteStrength
Film-coated tabletOral use30 mg
Film-coated tabletOral use60 mg
Film-coated tabletOral use90 mg
Tabletoral30 mg
Tabletoral60 mg
Tabletoral90 mg
Tablet, coatedoral30 mg/1
Tablet, coatedoral60 mg/1
Tablet, coatedoral90 mg/1
Prices
Unit descriptionCostUnit
Sensipar 90 mg tablet44.03USD tablet
Sensipar 60 mg tablet29.35USD tablet
Sensipar 30 mg tablet14.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2202879 No2005-08-302015-10-23Canada
US6011068 No1998-03-082018-03-08Us
US6031003 No1996-12-142016-12-14Us
US6211244 No1995-10-232015-10-23Us
US6313146 No1996-12-142016-12-14Us
US7829595 No2006-09-222026-09-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly soluble (in HCl salt form)Not Available
logP6.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.59e-05 mg/mLALOGPS
logP5.57ALOGPS
logP6.27ChemAxon
logS-6.8ALOGPS
pKa (Strongest Basic)10.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity100.12 m3·mol-1ChemAxon
Polarizability37.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Revital Lifshitz-Liron, “Process for the preparation of cinacalcet base.” U.S. Patent US20070259964, issued November 08, 2007.

US20070259964
General References
  1. Torres PU: Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr. 2006 Jul;16(3):253-8. [PubMed:16825031 ]
  2. Padhi D, Harris R: Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11. doi: 10.2165/00003088-200948050-00002. [PubMed:19566113 ]
  3. Dong BJ: Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005 Nov;27(11):1725-51. [PubMed:16368445 ]
External Links
ATC CodesH05BX01
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (278 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Cinacalcet.
AbirateroneThe serum concentration of Cinacalcet can be increased when it is combined with Abiraterone.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Cinacalcet.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Cinacalcet.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Cinacalcet.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Cinacalcet.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Cinacalcet.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Cinacalcet.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Cinacalcet.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Cinacalcet.
AmiodaroneThe metabolism of Cinacalcet can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Cinacalcet.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Cinacalcet.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Cinacalcet.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Cinacalcet.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Cinacalcet.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Cinacalcet.
AprepitantThe serum concentration of Cinacalcet can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Cinacalcet.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Cinacalcet.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Cinacalcet.
ArtemetherThe metabolism of Artemether can be decreased when combined with Cinacalcet.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Cinacalcet.
AtazanavirThe metabolism of Cinacalcet can be decreased when combined with Atazanavir.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Cinacalcet.
AtomoxetineThe metabolism of Cinacalcet can be decreased when combined with Atomoxetine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Cinacalcet.
AzithromycinThe metabolism of Cinacalcet can be decreased when combined with Azithromycin.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Cinacalcet.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Cinacalcet.
BepridilThe metabolism of Bepridil can be decreased when combined with Cinacalcet.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Cinacalcet.
BexaroteneThe serum concentration of Cinacalcet can be decreased when it is combined with Bexarotene.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Cinacalcet.
BoceprevirThe metabolism of Cinacalcet can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Cinacalcet can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Cinacalcet can be decreased when it is combined with Bosentan.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Cinacalcet.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Cinacalcet.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Cinacalcet.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Cinacalcet.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Cinacalcet.
BupropionThe metabolism of Bupropion can be decreased when combined with Cinacalcet.
BuspironeThe metabolism of Buspirone can be decreased when combined with Cinacalcet.
CaffeineThe metabolism of Cinacalcet can be decreased when combined with Caffeine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Cinacalcet.
CarbamazepineThe metabolism of Cinacalcet can be increased when combined with Carbamazepine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Cinacalcet.
CarteololThe metabolism of Carteolol can be decreased when combined with Cinacalcet.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Cinacalcet.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Cinacalcet.
CeritinibThe serum concentration of Cinacalcet can be increased when it is combined with Ceritinib.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Cinacalcet.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Cinacalcet.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Cinacalcet.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Cinacalcet.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Cinacalcet.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Cinacalcet.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Cinacalcet can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Cinacalcet can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Cinacalcet can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Cinacalcet.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Cinacalcet.
ClonidineThe metabolism of Clonidine can be decreased when combined with Cinacalcet.
ClotrimazoleThe metabolism of Cinacalcet can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Cinacalcet.
CobicistatThe metabolism of Cinacalcet can be decreased when combined with Cobicistat.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Cinacalcet.
ConivaptanThe serum concentration of Cinacalcet can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Cinacalcet can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cinacalcet.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Cinacalcet.
CyclosporineThe metabolism of Cinacalcet can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Cinacalcet can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Cinacalcet can be decreased when it is combined with Dabrafenib.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Cinacalcet.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Cinacalcet.
DarunavirThe metabolism of Cinacalcet can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Cinacalcet.
DasatinibThe serum concentration of Cinacalcet can be increased when it is combined with Dasatinib.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Cinacalcet.
DeferasiroxThe serum concentration of Cinacalcet can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Cinacalcet can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Cinacalcet.
DexamethasoneThe serum concentration of Cinacalcet can be decreased when it is combined with Dexamethasone.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Cinacalcet.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Cinacalcet.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Cinacalcet.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Cinacalcet.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Cinacalcet.
DihydroergotamineThe metabolism of Cinacalcet can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Cinacalcet can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Cinacalcet.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Cinacalcet.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Cinacalcet.
DonepezilThe metabolism of Donepezil can be decreased when combined with Cinacalcet.
DopamineThe metabolism of Dopamine can be decreased when combined with Cinacalcet.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Cinacalcet.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Cinacalcet.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Cinacalcet.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cinacalcet.
DoxycyclineThe metabolism of Cinacalcet can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Cinacalcet can be decreased when combined with Dronedarone.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Cinacalcet.
EfavirenzThe serum concentration of Cinacalcet can be decreased when it is combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Cinacalcet.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Cinacalcet.
EncainideThe metabolism of Encainide can be decreased when combined with Cinacalcet.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Cinacalcet.
EnzalutamideThe serum concentration of Cinacalcet can be decreased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Cinacalcet.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Cinacalcet.
ErythromycinThe metabolism of Cinacalcet can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Cinacalcet.
Eslicarbazepine acetateThe serum concentration of Cinacalcet can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Cinacalcet.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Cinacalcet.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Cinacalcet.
EtravirineThe serum concentration of Cinacalcet can be decreased when it is combined with Etravirine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cinacalcet.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Cinacalcet.
FlecainideThe metabolism of Flecainide can be decreased when combined with Cinacalcet.
FluconazoleThe metabolism of Cinacalcet can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Cinacalcet.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Cinacalcet.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Cinacalcet.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Cinacalcet.
FluvoxamineThe metabolism of Cinacalcet can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Cinacalcet.
FosamprenavirThe metabolism of Cinacalcet can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Cinacalcet can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Cinacalcet can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Cinacalcet can be increased when it is combined with Fusidic Acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Cinacalcet.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Cinacalcet.
GranisetronThe metabolism of Granisetron can be decreased when combined with Cinacalcet.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Cinacalcet.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Cinacalcet.
HalothaneThe metabolism of Halothane can be decreased when combined with Cinacalcet.
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cinacalcet resulting in a loss in efficacy.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Cinacalcet.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Cinacalcet.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Cinacalcet.
IdelalisibThe serum concentration of Cinacalcet can be increased when it is combined with Idelalisib.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Cinacalcet.
ImatinibThe metabolism of Cinacalcet can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Cinacalcet.
IndinavirThe metabolism of Cinacalcet can be decreased when combined with Indinavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Cinacalcet.
IsavuconazoniumThe metabolism of Cinacalcet can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Cinacalcet can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Cinacalcet can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Cinacalcet can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Cinacalcet.
KetoconazoleThe metabolism of Cinacalcet can be decreased when combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Cinacalcet.
LevodopaThe metabolism of Levodopa can be decreased when combined with Cinacalcet.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Cinacalcet.
LidocaineThe metabolism of Cinacalcet can be decreased when combined with Lidocaine.
LisurideThe metabolism of Lisuride can be decreased when combined with Cinacalcet.
LomustineThe metabolism of Lomustine can be decreased when combined with Cinacalcet.
LoperamideThe metabolism of Loperamide can be decreased when combined with Cinacalcet.
LopinavirThe metabolism of Cinacalcet can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Cinacalcet.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Cinacalcet.
LovastatinThe metabolism of Cinacalcet can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Cinacalcet can be increased when it is combined with Luliconazole.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Cinacalcet.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Cinacalcet.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Cinacalcet.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Cinacalcet.
MethadoneThe metabolism of Methadone can be decreased when combined with Cinacalcet.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Cinacalcet.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Cinacalcet.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Cinacalcet.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Cinacalcet.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Cinacalcet.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Cinacalcet.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cinacalcet.
MexiletineThe metabolism of Cinacalcet can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Cinacalcet.
MifepristoneThe metabolism of Cinacalcet can be decreased when combined with Mifepristone.
MinaprineThe metabolism of Minaprine can be decreased when combined with Cinacalcet.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Cinacalcet.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Cinacalcet.
MitotaneThe serum concentration of Cinacalcet can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Cinacalcet.
ModafinilThe serum concentration of Cinacalcet can be decreased when it is combined with Modafinil.
MorphineThe metabolism of Morphine can be decreased when combined with Cinacalcet.
NafcillinThe serum concentration of Cinacalcet can be decreased when it is combined with Nafcillin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Cinacalcet.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Cinacalcet.
NefazodoneThe metabolism of Cinacalcet can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Cinacalcet can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Cinacalcet can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Cinacalcet.
NevirapineThe metabolism of Cinacalcet can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Cinacalcet.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Cinacalcet.
NicotineThe metabolism of Nicotine can be decreased when combined with Cinacalcet.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Cinacalcet.
NilotinibThe metabolism of Cinacalcet can be decreased when combined with Nilotinib.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Cinacalcet.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Cinacalcet.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Cinacalcet.
OlaparibThe metabolism of Cinacalcet can be decreased when combined with Olaparib.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Cinacalcet.
OsimertinibThe serum concentration of Cinacalcet can be increased when it is combined with Osimertinib.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Cinacalcet.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Cinacalcet.
PalbociclibThe serum concentration of Cinacalcet can be increased when it is combined with Palbociclib.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Cinacalcet.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Cinacalcet.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Cinacalcet.
Peginterferon alfa-2bThe serum concentration of Cinacalcet can be increased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Cinacalcet.
PentobarbitalThe metabolism of Cinacalcet can be increased when combined with Pentobarbital.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Cinacalcet.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Cinacalcet.
PethidineThe metabolism of Pethidine can be decreased when combined with Cinacalcet.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Cinacalcet.
PhenforminThe metabolism of Phenformin can be decreased when combined with Cinacalcet.
PhenobarbitalThe metabolism of Cinacalcet can be increased when combined with Phenobarbital.
PhenytoinThe metabolism of Cinacalcet can be increased when combined with Phenytoin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cinacalcet.
PindololThe metabolism of Pindolol can be decreased when combined with Cinacalcet.
PiperazineThe metabolism of Piperazine can be decreased when combined with Cinacalcet.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Cinacalcet.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Cinacalcet.
PosaconazoleThe metabolism of Cinacalcet can be decreased when combined with Posaconazole.
PrimidoneThe metabolism of Cinacalcet can be increased when combined with Primidone.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Cinacalcet.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Cinacalcet.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Cinacalcet.
PromethazineThe metabolism of Promethazine can be decreased when combined with Cinacalcet.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Cinacalcet.
PropofolThe metabolism of Propofol can be decreased when combined with Cinacalcet.
PropranololThe metabolism of Propranolol can be decreased when combined with Cinacalcet.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Cinacalcet.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Cinacalcet.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Cinacalcet.
QuinineThe metabolism of Quinine can be decreased when combined with Cinacalcet.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Cinacalcet.
RanolazineThe metabolism of Cinacalcet can be decreased when combined with Ranolazine.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Cinacalcet.
repinotanThe metabolism of repinotan can be decreased when combined with Cinacalcet.
RifabutinThe metabolism of Cinacalcet can be increased when combined with Rifabutin.
RifampicinThe metabolism of Cinacalcet can be increased when combined with Rifampicin.
RifapentineThe metabolism of Cinacalcet can be increased when combined with Rifapentine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Cinacalcet.
RitonavirThe metabolism of Cinacalcet can be decreased when combined with Ritonavir.
RopiniroleThe metabolism of Cinacalcet can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Cinacalcet.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Cinacalcet.
SaquinavirThe metabolism of Cinacalcet can be decreased when combined with Saquinavir.
SertindoleThe metabolism of Sertindole can be decreased when combined with Cinacalcet.
SertralineThe metabolism of Sertraline can be decreased when combined with Cinacalcet.
SildenafilThe metabolism of Cinacalcet can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Cinacalcet can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Cinacalcet can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Cinacalcet.
SparteineThe metabolism of Sparteine can be decreased when combined with Cinacalcet.
St. John's WortThe serum concentration of Cinacalcet can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Cinacalcet can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Cinacalcet can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Cinacalcet.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cinacalcet resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Cinacalcet.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Cinacalcet.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Cinacalcet.
TelaprevirThe metabolism of Cinacalcet can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Cinacalcet can be decreased when combined with Telithromycin.
TenofovirThe metabolism of Cinacalcet can be decreased when combined with Tenofovir.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Cinacalcet.
TeriflunomideThe serum concentration of Cinacalcet can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Cinacalcet.
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Cinacalcet.
TheophyllineThe metabolism of Cinacalcet can be decreased when combined with Theophylline.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cinacalcet.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Cinacalcet.
TiclopidineThe metabolism of Cinacalcet can be decreased when combined with Ticlopidine.
TimololThe metabolism of Timolol can be decreased when combined with Cinacalcet.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Cinacalcet.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Cinacalcet.
TocilizumabThe serum concentration of Cinacalcet can be decreased when it is combined with Tocilizumab.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Cinacalcet.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Cinacalcet.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cinacalcet.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Cinacalcet.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Cinacalcet.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Cinacalcet.
VemurafenibThe serum concentration of Cinacalcet can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Cinacalcet can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Cinacalcet can be decreased when combined with Verapamil.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Cinacalcet.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Cinacalcet.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Cinacalcet.
VoriconazoleThe metabolism of Cinacalcet can be decreased when combined with Voriconazole.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Cinacalcet.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Cinacalcet.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Cinacalcet.
ZiprasidoneThe metabolism of Cinacalcet can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Cinacalcet.
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Cinacalcet.
Food Interactions
  • Food markedly increases product bioavailability.
  • Peak levels and area under curve (drug exposure) are increased (82% and 68% respectively) when product is taken with a lipid-rich meal.
  • Take with food or soon after a meal.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
Senses changes in the extracellular concentration of calcium ions. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system.
Gene Name:
CASR
Uniprot ID:
P41180
Molecular Weight:
120672.385 Da
References
  1. de Francisco AL: Cinacalcet HCl: a novel therapeutic for hyperparathyroidism. Expert Opin Pharmacother. 2005 Mar;6(3):441-52. [PubMed:15794735 ]
  2. Rothe HM, Shapiro WB, Sun WY, Chou SY: Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogenet Genomics. 2005 Jan;15(1):29-34. [PubMed:15864123 ]
  3. Tasic V: Management of renal osteodystrophy in children. Turk J Pediatr. 2005;47 Suppl:13-8. [PubMed:15884662 ]
  4. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM: Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005 Oct;20(10):2186-93. Epub 2005 Jul 19. [PubMed:16030053 ]
  5. Cunningham J: Management of secondary hyperparathyroidism. Ther Apher Dial. 2005 Aug;9 Suppl 1:S35-40. [PubMed:16109140 ]
  6. Eriguchi R, Umakoshi J, Tominaga Y, Sato Y: Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl. NDT Plus. 2008 Aug;1(4):218-220. Epub 2008 May 25. [PubMed:19461861 ]
  7. Belozeroff V, Goodman WG, Ren L, Kalantar-Zadeh K: Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009 Mar;4(3):673-9. doi: 10.2215/CJN.03790808. Epub 2009 Mar 4. [PubMed:19261825 ]
  8. Meola M, Petrucci I, Barsotti G: Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2009 Mar;24(3):982-9. doi: 10.1093/ndt/gfn654. Epub 2009 Jan 30. [PubMed:19181759 ]
  9. Drueke TB, Ritz E: Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol. 2009 Jan;4(1):234-41. doi: 10.2215/CJN.04520908. Epub 2008 Dec 3. [PubMed:19056615 ]
  10. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Padhi D, Harris R: Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11. doi: 10.2165/00003088-200948050-00002. [PubMed:19566113 ]
  2. Dong BJ: Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005 Nov;27(11):1725-51. [PubMed:16368445 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Padhi D, Harris R: Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11. doi: 10.2165/00003088-200948050-00002. [PubMed:19566113 ]
  2. Dong BJ: Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005 Nov;27(11):1725-51. [PubMed:16368445 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Padhi D, Harris R: Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11. doi: 10.2165/00003088-200948050-00002. [PubMed:19566113 ]
  2. Dong BJ: Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005 Nov;27(11):1725-51. [PubMed:16368445 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:26